Lægen skal sikre den nødvendige dosisjustering af CELSENTRI, når det anvendes sammen med CYP3A4- hæmmere og/ eller - induktorer, da maravirockoncentrationer og den terapeutiske effekt kan påvirkes (se pkt.
Dose adjustment: physicians should ensure that appropriate dose adjustment of CELSENTRI is made when CELSENTRI is co-administered with CYP3A4 inhibitors and/ or inducers since maraviroc concentrations and its therapeutic effects may be affected (see sections 4.2 and 4.5).